Evaluation of the safety and immunogenicity of the ERAGS-GFP oral rabies vaccine in dogs

Rabies is a fatal zoonotic disease primarily transmitted through dog bites, making oral rabies vaccines critical for disease control. This study evaluated the immunogenicity of the ERAGS-GFP oral rabies vaccine strain in dogs. To optimize viral production, we examined cell density, multiplicity of infection (MOI), and freeze-thaw cycles. Safety was assessed via clinical monitoring, body temperature, and weight changes. Immunogenicity was evaluated using rabies virus neutralizing antibody (VNA) titers. Vero cells at MOI 2 with 3 freeze-thaw cycles yielded the highest viral titers. Vaccinated dogs showed no clinical symptoms and developed sustained protective VNA titers, demonstrating ERAGS-GFP's efficacy in rabies control.